Clinical trials: Recurrent Glioblastoma
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy…
- Trial name
- NCT05432804
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Selinexor
- Where
- 39 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma (GBM), High Grade Gliomas
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
The goal of this clinical trial is to first define the Safety and Optimal Biological Dose (OBD) of study drug TGX-007 and to then further investigate the safety and efficacy in patients with newly diagnosed or recurrent…
- Conditions
- Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
- Trial name
- ADePT (NCT07346144)
- Testing
- TGX-007, Valaciclovir
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Trogenix ltd
Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients…
- Trial name
- NCT07544992
- Testing
- Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Recurrent Glioblastoma, Recurrent Malignant Glioma
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is…
- Conditions
- Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
- Trial name
- NCT04214392
- Testing
- Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery), Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- City of Hope Medical Center
Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4…
- Conditions
- Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
- Trial name
- NCT06815029
- Testing
- Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Recurrent Glioblastoma IDH Wildtype
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
The purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with resected recurrent glioblastoma (rGBM) via convection enhanced…
- Trial name
- NCT06455605
- Testing
- D2C7-IT, 2141 V11
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Darell Bigner
Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement…
- Conditions
- Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant, Recurrent Astrocytoma, IDH-Mutant
- Trial name
- NCT06860594
- Testing
- Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy
- Where
- 43 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Recurrent or Progressive Glioblastoma
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.
This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recurrent or progressive GBM (Cohort C) (collectively called 'indication…
- Conditions
- Advanced Solid Tumors, Recurrent or Progressive Glioblastoma, Relapse or Refractory Myeloid Malignancies
- Trial name
- TelOscope (NCT07779798)
- Testing
- CBX-663
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Crossbow Therapeutics, Inc.
Progressive Glioblastoma, Recurrent Glioblastoma
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come…
- Trial name
- NCT06325683
- Testing
- Biopsy Procedure, Biospecimen Collection, Lomustine
- Where
- 325 sites in United States
- Volunteers
- 184 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Brain Tumor
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to compare the cannabinoid Nabiximols with placebo in patients with recurrent MGMT methylated glioblastoma (GBM) treated with temozolomide…
- Conditions
- Glioblastoma, Brain Tumor, Cannabis, Brain Tumor, Recurrent
- Trial name
- ARISTOCRAT (NCT05629702)
- Testing
- Nabiximols, Temozolomide
- Where
- 17 sites in United Kingdom
- Volunteers
- 122 people
- Sponsor
- University of Birmingham
Astrocytoma, Glioma
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months.
- Conditions
- Astrocytoma, Glioma, Recurrent Glioblastoma
- Trial name
- NCT06344130
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal.
- Conditions
- Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor
- Trial name
- NCT07416188
- Testing
- LMP744, Conventional Surgery or Biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients.
- Conditions
- Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
- Trial name
- NCT03423628
- Testing
- Radiation Therapy, AZD1390
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
Recurrent Glioblastoma, Refractory Glioblastoma
Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma
This is a pilot phase I, single-center, open-label, single-arm study to evaluate the feasibility, safety, tolerability, and preliminary efficacy of repeated intracranial infusions of BP102 in adults with recurrent or refractory…
- Trial name
- NCT04385173
- Testing
- BP102 (B7-H3 CAR-T)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Recurrent Glioblastoma
An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM
The purpose of this study is to test Y90 glass microspheres for people with recurrent brain cancer. Participation in this study will help researchers find the best dose for the treatment of the disease.
- Trial name
- ODYSSEY (NCT07867886)
- Testing
- Device: TheraSphere GBM treatment of TheraSphere GBM device
- Where
- 5 sites in France, Germany and 2 more
- Volunteers
- 30 people
- Sponsor
- Boston Scientific Corporation
Recurrent Glioblastoma
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.
- Trial name
- ASPIRE (NCT06389591)
- Testing
- pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Recurrent Glioma (Glioblastoma Multiforme)
GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent Glioma
This study is being done to see if a Ketogenic Diet (KD) or short-term Ketone supplement (KS) is feasible and safe for patients with recurrent Glioma who are undergoing a clinically indicated surgery.
- Trial name
- GLAD-KE (NCT07852975)
- Testing
- Arm 1 will use Ketone supplement 80 gm daily, Arm 2 will follow Ketogenic Diet 7 days leading up to the clinically indicated surgery.
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma
Fimepinostat in Treating Brain Tumors in Children and Young Adults
This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back.
- Conditions
- Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma
- Trial name
- PNOC016 (NCT03893487)
- Testing
- Fimepinostat, Therapeutic Conventional Surgery
- Where
- 19 sites in United States, Switzerland
- Volunteers
- 30 people
- Sponsor
- Sabine Mueller, MD, PhD
High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent).
- Conditions
- High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
- Trial name
- NCT05465954
- Testing
- Biospecimen Collection, Efineptakin alfa, Pembrolizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Mayo Clinic
Glioblastoma, Recurrent Glioblastoma
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls.
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM
- Trial name
- SONOBIRD (NCT05902169)
- Testing
- SonoCloud-9 (SC9), Carboplatin, Lomustine
- Where
- 56 sites in United States, Austria and 9 more
- Volunteers
- 560 people
- Sponsor
- CarThera